[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-hepatic-pruritus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-hepatic-pruritus":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100657955","phase-2-nemolizumab-for-the-treatment-of-moderate-to-severe-chronic-hepatic-pruritus-100657955",false,"NCT07843420","Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus","Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: An Open-Label, Single-Arm, Exploratory Study","Inclusion Criteria:\n\n* Cholestatic pruritus secondary primary biliary sclerosis (PBS) or primary sclerosing cholangitis (PSC)\n* Pruritus that is chronic in duration (greater equal to 6 months)\n* Pruritus severity with a peak pruritus numerical rating score of ≥ 5 (moderate severity)\n* Model for End-Stage Liver Disease (MELD) score \\\u003C 15. This will capture patients with chronic stable liver disease without significant comorbid conditions and\u002For signs of rapidly progressive or decompensated liver failure\n* Willingness and ability to comply with scheduled clinic visits, physical exams, laboratory tests, questionnaires, effective contraception use, and other trial procedures\n\nExclusion Criteria:\n\n* Pruritus due to a primary inflammatory skin dermatosis or other forms of psychogenic pruritus utilizing skin biopsies to exclude as needed\n* Pregnant females. Urine pregnancy test required at screening\n* History of intrahepatic cholestasis of pregnancy\n* Any form of chronic hepatic pruritus associated with underlying malignancy\n* Liver transplant recipients\n* Drug-induced liver pruritus\n* ALT or AST greater than 3 times the upper limit of normal or total bilirubin greater than 2 times upper normal limit\n* Advanced liver disease indicators including, ascites requiring therapeutic paracentesis, history of spontaneous bacterial peritonitis, any grade of hepatic encephalopathy, or a documented history of variceal bleeding within the preceding six months\n* Severe coagulopathy with INR \\> 15\n* Any form of acute cholestatic liver disease\n* Allergy to nemolizumab or its ingredients\n* Inability to provide informed consent","ALL","18 Years",{"count":19,"type":20},15,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this research is to investigate the efficacy of nemolizumab in the treatment of adults with moderate to severe chronic hepatic pruritus.",[26,27,28,29,30],"Chronic Hepatic Pruritus","Cholestatic Liver Disease","Primary Biliary Cholangitis","Cholestasis","Primary Sclerosing Cholangitis","NOT_YET_RECRUITING","2026-09-21",{"date":34,"type":35},"2026-09-28","ACTUAL",{"date":37,"type":20},"2026-11",{"date":39,"type":20},"2028-11",{"name":41,"class":42},"Mayo Clinic","OTHER"]